Bolt Biotherapeutics (Bolt Biotherapeutics) GF Score : 47/100 (As of May. 22, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics GF Score?

Bolt Biotherapeutics has the GF Score of 47, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 5/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Bolt Biotherapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Bolt Biotherapeutics's GF Score

For the Biotechnology subindustry, Bolt Biotherapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bolt Biotherapeutics's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's GF Score falls into.

Bolt Biotherapeutics (NAS:BOLT) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Bolt Biotherapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

6LP:Germany

Address

900 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Executives

William P. Quinn	officer: Chief Financial Officer	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman	director	575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner	director	C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee	director	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte	director
Miller Richard A Md	director	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah	director	2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro	officer: Chief Business Officer	C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman	director, officer: Chief Executive Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez	officer: Chief Medical Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063